APOE and Alzheimer disease: APOE4 carriers had higher odds of incident AD and dementia diagnosis within 17 years compared to non-carriers (Table 1, OR, 95% CI: AD, 3.27, 2.35–4.55; ACD: 2.14, 1.74–2.63).